EnBio Holdings, Inc. AI Stock Analysis
Want to see JP:6092 full AI Analyst Report?
EnBio Holdings, Inc. (6092) AI Stock Analysis
EnBio Holdings, Inc.
(TSE/TYO:6092)
The overall score is very low, driven primarily by weak financial performance and bearish technicals. The company's inability to convert strong revenue growth into net income and cash flow is a major concern. This is compounded by a stock price in a clear downtrend, trading below all key moving averages with deeply oversold momentum. The high P/E ratio adds further downside risk given the earnings deterioration.
EnBio Holdings, Inc. (6092) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 4.91B
- Dividend Yield
- 1.45%
- Average Volume (3M)
- 22.98K
- Price to Earnings (P/E)
- 42.9
- Beta (1Y)
- 0.51
- Revenue Growth
- 22.25%
- EPS Growth
- -80.27%
- Country
- Japan
- Employees
- 113
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Environmental Services
EnBio Holdings, Inc. Business Overview & Revenue Model
Company Description
EnBio Holdings, Inc. engages in the provision of soil pollution countermeasure services. It operates through the following segments: Soil Pollution Countermeasures, Brownfield Utilization, and Natural Energy. The Soil Pollution Countermeasures segmen...
How the Company Makes Money
null
EnBio Holdings, Inc. Financial Statement Overview
Summary
Financial performance is weak. While revenue growth is strong, net margin has collapsed to 2.1% and free cash flow is minimal at ¥119 million. The Income Statement (38), Balance Sheet (45), and Cash Flow (32) scores all reflect significant profitability and cash generation concerns.
Income Statement
38NegativeBalance Sheet
45NeutralCash Flow
32Negative| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.39B | 10.67B | 12.63B | 9.58B | 8.12B | 8.99B |
| Gross Profit | 2.67B | 2.65B | 3.69B | 2.48B | 2.76B | 2.43B |
| EBITDA | 1.26B | 1.35B | 2.16B | 1.25B | 1.76B | 1.59B |
| Net Income | 579.86M | 452.69M | 265.00M | 708.76M | 812.06M | 654.06M |
Balance Sheet | ||||||
| Total Assets | 22.24B | 21.20B | 22.85B | 19.31B | 17.35B | 16.37B |
| Cash, Cash Equivalents and Short-Term Investments | 3.76B | 3.29B | 4.04B | 3.60B | 2.83B | 2.37B |
| Total Debt | 10.29B | 10.10B | 10.65B | 8.62B | 8.90B | 8.58B |
| Total Liabilities | 12.75B | 11.96B | 13.52B | 10.72B | 10.49B | 10.40B |
| Stockholders Equity | 9.41B | 9.14B | 9.25B | 8.49B | 6.79B | 5.89B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.44B | 119.00M | 584.36M | 826.37M | 1.25B |
| Operating Cash Flow | 0 | 21.92M | 1.17B | 1.66B | 1.99B | 2.41B |
| Investing Cash Flow | 0 | -1.60B | -891.00M | -1.58B | -1.77B | -1.48B |
| Financing Cash Flow | 0 | 1.27B | 460.00M | 638.92M | 240.73M | -534.92M |
EnBio Holdings, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6092, the sentiment is Negative. The current price of 620.00 is below the 20-day moving average (MA) of 739.30, below the 50-day MA of 772.12, and below the 200-day MA of 755.32, indicating a bearish trend. The MACD of -31.95 indicates Positive momentum. The RSI at 25.57 is Positive, neither overbought nor oversold. The STOCH value of 5.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6092.
EnBio Holdings, Inc. Peers Comparison
Overall Rating
JP:798768Neutral
JP:932567Neutral
JP:704964.65Neutral
JP:979164Neutral
JP:480961Neutral
JP:609238Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 68Neutral | JPY 13.82B | 5.57 | ― | 4.11% | -0.27% | 41.12% | |
| 67Neutral | JPY 10.88B | 9.19 | ― | 3.40% | 20.43% | 35.08% | |
| 65Neutral | JPY 5.86B | -29.80 | ― | ― | -13.95% | -133.99% | |
| 64Neutral | JPY 8.03B | 6.08 | ― | 3.57% | 0.94% | 6.37% | |
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| 61Neutral | JPY 18.99B | 7.89 | ― | 3.85% | 7.06% | 15.39% | |
| 38Underperform | JPY 5.05B | 42.89 | ― | 1.45% | 22.25% | -80.27% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:6092 | EnBio Holdings, Inc. | 620.00 | 29.83 | 5.05% | |
| JP:4809 | Paraca Inc. | 1871.00 | -125.08 | -6.27% | |
| JP:7049 | SHIKIGAKU Co., Ltd. | 695.00 | -154.00 | -18.14% | |
| JP:7987 | Nakabayashi Co., Ltd. | 535.00 | 10.20 | 1.94% | |
| JP:9325 | PHYZ Holdings, Inc. | 1000.00 | -8.62 | -0.85% | |
| JP:9791 | Biken Techno Corporation | 1065.00 | -172.51 | -13.94% |
EnBio Holdings, Inc. Corporate Events
EnBio Holdings Reports Six-Month Consolidated Results
EnBio Holdings, Inc. reported consolidated results for the six months ended September 30, 2026. Net sales increased 1.3% year over year to ¥5,756 million, operating profit rose 8.6% to ¥712 million, and ordinary profit grew 7.3% to ¥642 million, whil...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 18, 2026
